1-(Naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 1-(Naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol
• 化学式: C₂₀H₁₉NO₂
• 分子量: 305.4
• InChiKey: WTHURCRQFHKJKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  52.5
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions
  申请人：Yun-Choi Hye-Sook

  公开号：US20060058346A1

  公开（公告）日：2006-03-16

  The disclosure concerns novel enantiomers of tetrahydroisoquinoline derivatives and their pharmaceutically acceptable salts, their preparations and pharmaceutical compositions. The enantiomers of tetrahydroisoquinoline derivatives are provided which are useful in stimulating heart rate and hypotensive activity, inhibitory activity against platelet aggregation, and suppressive against inducible NO synthase. The enantiomers of tetrahydroisoquinoline derivatives and their pharmaceutically acceptable salts are effective for treating congestive heart failure, hypertension, thrombosis, inflammation, septicemia, cardiac insufficiency, and disseminated intravascular coagulopathy.

  该披露涉及四氢异喹啉衍生物的新手性异构体及其药学上可接受的盐、其制备和制药组合物。提供了四氢异喹啉衍生物的手性异构体，其对于刺激心率和降压活性、抑制血小板聚集活性以及对可诱导的一氧化氮合酶具有抑制作用是有用的。四氢异喹啉衍生物的手性异构体及其药学上可接受的盐对于治疗充血性心力衰竭、高血压、血栓形成、炎症、败血症、心脏功能不全和弥漫性血管内凝血是有效的。
• PHARMACEUTICAL COMPOSITIONS CONTAINING TETRAHYDROISOQUINOLINE COMPOUNDS
  申请人：Korea Institute of Science and Technology

  公开号：EP1124554A1

  公开（公告）日：2001-08-22
• US6562837B1
  申请人：——

  公开号：US6562837B1

  公开（公告）日：2003-05-13
• [EN] PHARMACEUTICAL COMPOSITIONS CONTAINING TETRAHYDROISOQUINOLINE COMPOUNDS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES RENFERMANT DES COMPOSES DE TETRAHYDROISOQUINOLEINE
  申请人：KOREA INST SCI & TECH

  公开号：WO2000023078A1

  公开（公告）日：2000-04-27

  Disclosed are pharmaceutical compositions for the treatment and prophylaxis of heart failure, thrombosis, iNOS-induced tissue injury, septicemia, and disseminated intravascular coagulation. The compositions comprise, as a pharmacologically active ingredient, the compounds represented by chemical formulas (1) and (2), each of them showing heart stimulating activity, hypotensive activity, inhibitory activity against platelet aggregation, and suppressive activity against iNOS expression in combination and at once.